Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
3 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.

Icatibant relieves acute attacks in hereditary angioedema

11 Dec 2019

The selective bradykinin B2 receptor antagonist icatibant proves to be effective and safe for managing acute attacks in Japanese patients with hereditary angioedema (HAE), according to the results of a small phase III open-label trial.

In the trial, eight HAE patients who had an attack affecting the skin (n=4), abdomen (n=3) or larynx (n=1) received icatibant 30 mg via subcutaneous injection in the abdomen administered by the patient or a healthcare professional.

Symptom relief occurred after a median of 1.75 hours (95 percent confidence interval [CI], 1.00–2.50) of treatment, with all patients achieving symptom relief within 5 hours after administration.

The time to maximum plasma concentration of icatibant was 1.79 hours, with the maximum plasma concentration being 405 ng/ml.

In terms of safety, injection site reaction occurred in seven patients. There were three adverse events recorded: worsening of HAE 29 hours after treatment, repeat HAE attack 18.3 hours after treatment and a headache.

Regardless of the small number of patients included in the study, the findings confirm that subcutaneous icatibant administration may quickly relieve the symptoms of acute HAE attacks, according to researchers.

An autosomal-dominant genetic disease characterized by recurrent swelling episodes, HAE attacks are unpredictable in terms of onset, duration, severity, frequency and anatomical location. Furthermore, attacks affecting the larynx may be life-threatening. [Am J Gastroenterol 2006;101:619-627; J Allergy Clin Immunol 2012;130:692-697]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
3 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.